{"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}],"groups":[{"description":"In ALK genetic event positive participants with ALCL, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"BG000","title":"ALCL Arm"},{"description":"In ALK genetic event positive participants with IMT, crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"BG001","title":"IMT Arm"},{"description":"In ALK genetic event positive participants with other tumors (excluding non-small cell lung cancer), crizotinib 250 mg twice daily (BID) was administered orally at approximately the same time each day on a continuous daily dosing schedule. Crizotinib was allowed to be taken without regard to meals. Cycles were defined in 21 day periods. Participants could have continued treatment with crizotinib on this study as long as there was evidence of clinical benefit in the judgment of the Investigator.","id":"BG002","title":"Other Tumors"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"15.0","upperLimit":"37.0","value":"25.0"},{"groupId":"BG001","lowerLimit":"16.0","upperLimit":"73.0","value":"32.0"},{"groupId":"BG002","lowerLimit":"18.0","upperLimit":"73.0","value":"49.0"},{"groupId":"BG003","lowerLimit":"15.0","upperLimit":"73.0","value":"32.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}],"title":"Overall Population"},{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"15.0","upperLimit":"16.0","value":"15.0"},{"groupId":"BG001","lowerLimit":"16.0","upperLimit":"17.0","value":"16.5"},{"groupId":"BG003","lowerLimit":"15.0","upperLimit":"17.0","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"units":"Participants"}],"title":"Pediatric Population"}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"The data for age was provided for the overall population and the pediatric population. Number Analyzed for Overall Population = Number of participants (regardless of age) with the corresponding type(s) of tumor, who were enrolled and treated in this study. Number Analyzed for Pediatric Population = Number of participants \\<18 years of age with the corresponding type(s) of tumor, who were enrolled and treated in this study.","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"title":"<18"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"35"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}]}],"description":"Number Analyzed for Overall Population = Number of participants (regardless of age) with the corresponding type(s) of tumor, who were enrolled and treated in this study.","paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"25"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}],"title":"Overall population"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"units":"Participants"}],"title":"Pediatric Population"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The data for sex was provided for the overall population and the pediatric population. Number Analyzed for Overall Population = Number of participants (regardless of age) with the corresponding type(s) of tumor, who were enrolled and treated in this study. Number Analyzed for Pediatric Population = Number of participants \\<18 years of age with the corresponding type(s) of tumor, who were enrolled and treated in this study.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"23"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"21"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"44"}],"units":"Participants"}],"title":"Asian"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"units":"Participants"}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"units":"Participants"}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"}],"units":"Participants"}],"title":"Asia"}],"description":"Racial Designation for pediatric population.","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Number Analyzed for Pediatric Population = Number of participants \\<18 years of age with the corresponding type(s) of tumor, who were enrolled and treated in this study.","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Baseline population included all enrolled participants who received at least one dose of study intervention."}